Benitec Biopharma Inc. Announces Proposed Public Offering

Core Points - Benitec Biopharma Inc. has initiated an underwritten public offering of its common stock and a concurrent registered direct offering with Suvretta Capital [1] - The offerings are expected to close on November 7, 2025, subject to customary closing conditions [1] - The underwriters have a 30-day option to purchase up to 15% additional shares of common stock sold in the offering [1] Company Overview - Benitec Biopharma Inc. is a clinical-stage biotechnology company based in Hayward, California, focusing on novel genetic medicines [5] - The company utilizes a proprietary "Silence and Replace" platform that combines RNA interference with gene therapy to treat chronic and life-threatening conditions, such as Oculopharyngeal Muscular Dystrophy (OPMD) [5]